Nashed et al. reported that the treatment of H460 non-small cell lung cancer (NSCLC) cells with the SCD1 inhibitor, CVT-11127 or CVT-12012, potentiated the gefitinib-dependent inhibition of cancer cell proliferation [79]. This evidence concerns the gene SCD and non-small cell lung carcinoma.